Exchange: NASDAQ·Updated 02:54 PM EDT
SPRO logo

SPRO Spero Therapeutics Inc

$1.13
$0.015
(1.32%)
Today
EarningsNov 12
Mkt Cap$66.39M
Vol137,982.00

About SPRO

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
51

Neutral Sentiment

How do you feel about SPRO?

Advertisement|Remove ads.